

# Martin BÄJgemann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3625944/publications.pdf>

Version: 2024-02-01

47  
papers

2,097  
citations

361413  
20  
h-index

302126  
39  
g-index

50  
all docs

50  
docs citations

50  
times ranked

2211  
citing authors

#	ARTICLE	IF	CITATIONS
1	German Multicenter Study Investigating $^{177}\text{Lu}$ -PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2017, 58, 85-90.	5.0	646
2	Early side effects and first results of radioligand therapy with $^{177}\text{Lu}$ -DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. <i>EJNMMI Research</i> , 2015, 5, 114.	2.5	250
3	Radioligand Therapy With $^{177}\text{Lu}$ -PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, 522-528.	1.3	153
4	$^{177}\text{Lu}$ -PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1663-1670.	6.4	145
5	Comparative Assessment of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG Gene Fusion with the Serum $^{25}\text{OH}$ -Vitamin D-Binding Protein-Based Prostate Health Index for Detection of Prostate Cancer. <i>Clinical Chemistry</i> , 2013, 59, 280-288.	3.2	95
6	Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving $^{177}\text{Lu}$ -PSMA-617 Radioligand Therapy. <i>Theranostics</i> , 2020, 10, 7812-7820.	10.0	75
7	Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with $^{177}\text{Lu}$ -PSMA-617. A WARMTH multicenter study (the 617 trial). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 113-122.	6.4	72
8	PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving $^{177}\text{Lu}$ -PSMA-617 radioligand therapy in a bicentric analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1200-1210.	6.4	72
9	Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving $^{177}\text{Lu}$ -PSMA-617. <i>Theranostics</i> , 2019, 9, 4841-4848.	10.0	62
10	Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid. <i>Oncotarget</i> , 2018, 9, 9867-9874.	1.8	57
11	The percentage of prostate-specific antigen (PSA) isoform $^{2}\text{proPSA}$ and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged $\geq 65$ years. <i>BIU International</i> , 2016, 117, 72-79.	2.5	55
12	Radioligand therapy using $^{177}\text{Lu}$ -PSMA-617 in mCRPC: a pre-VISION single-center analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2106-2112.	6.4	37
13	Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer. <i>BMC Cancer</i> , 2016, 16, 214.	2.6	35
14	Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study. <i>BMC Cancer</i> , 2019, 19, 60.	2.6	33
15	Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST. <i>Oncotarget</i> , 2017, 8, 4268-4276.	1.8	33
16	The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 73-81.	2.4	31
17	The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone. <i>International Journal of Molecular Sciences</i> , 2017, 18, 380.	4.1	29
18	Histologic Subtype of Metastatic Renal Cell Carcinoma Predicts Response to Combined Immunochemotherapy with Interleukin 2, Interferon $\gamma$ and 5-Fluorouracil. <i>European Urology</i> , 2007, 51, 1625-1632.	1.9	26

#	ARTICLE	IF	CITATIONS
19	Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving <sup>177</sup> Lu-PSMA-617 Radioligand Therapy. <i>Theranostics</i> , 2020, 10, 7645-7655.	10.0	23
20	SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). <i>European Journal of Cancer</i> , 2019, 107, 37-45.	2.8	21
21	Prostate-specific Membrane Antigen-based Imaging of Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 279-287.	3.1	17
22	Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC). <i>Current Cancer Drug Targets</i> , 2015, 15, 243-255.	1.6	15
23	Evaluation of <sup>68</sup> Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving <sup>177</sup> Lu-PSMA-617 Therapy: A Radiomics Analysis. <i>Cancers</i> , 2021, 13, 3849.	3.7	15
24	Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate. <i>PLoS ONE</i> , 2016, 11, e0161959.	2.5	15
25	Additional Local Therapy for Liver Metastases in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Systemic PSMA-Targeted Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 723-728.	5.0	13
26	Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging. <i>Annals of Nuclear Medicine</i> , 2022, 36, 293-301.	2.2	13
27	Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives. <i>Cancers</i> , 2021, 13, 3715.	3.7	11
28	Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management. <i>Cancers</i> , 2021, 13, 3556.	3.7	9
29	Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1520.	4.1	8
30	Using Data from a Sickness Fund Claims Database to Assess the Treatment Patterns and Healthcare Resource Utilization among Patients with Metastatic Renal Cell Carcinoma in Germany. <i>Urologia Internationalis</i> , 2020, 104, 982-993.	1.3	6
31	A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy setting. <i>Oncotarget</i> , 2019, 10, 5082-5091.	1.8	4
32	Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma after Prior Therapy: Interim Results from the Noninterventional NORA Study. <i>European Urology Focus</i> , 2022, 8, 1289-1299.	3.1	4
33	ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis. <i>Translational Andrology and Urology</i> , 2021, 10, 0-0.	1.4	3
34	Detecting predictive androgen receptor modifications in circulating prostate cancer cells.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5067-5067.	1.6	3
35	Artificial Intelligence-Based Prognostic Model for Urologic Cancers: A SEER-Based Study. <i>Cancers</i> , 2022, 14, 3135.	3.7	3
36	Second-line treatment of advanced urothelial cancer with paclitaxel and RAD001 (everolimus) in a German phase II trial (AUO trial AB 35/09).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4590-4590.	1.6	2

#	ARTICLE	IF	CITATIONS
37	Dynamic changes of alkaline phosphatase as surrogate for best clinical benefit and overall survival during very early abiraterone therapy compared to PSA-changes in bone metastatic castration resistant prostate cancer.. Journal of Clinical Oncology, 2015, 33, 260-260.	1.6	2
38	Use of [-2]proPSA and prostate health index (phi) to improve the diagnostic accuracy of prostate cancer compared to t-PSA and %f-PSA in young men (â‰‰ 65 years old).. Journal of Clinical Oncology, 2013, 31, 5074-5074.	1.6	0
39	The effect of [-2]proPSA and prostate health index (phi) on the accuracy of the prediction of initial and repeat prostate biopsies compared to tPSA and percent fPSA in young men (age 65 or younger).. Journal of Clinical Oncology, 2014, 32, 171-171.	1.6	0
40	Indicators of clinical response to abiraterone acetate (AA) in men with metastatic castration-resistant-prostate-cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, e16066-e16066.	1.6	0
41	Prediction of postoperative histology in patients with prostate cancer using preoperative Ga-68-PSMA-PET/CT.. Journal of Clinical Oncology, 2016, 34, 144-144.	1.6	0
42	The role of fPSA, [-2]proPSA and the Prostate Health Index for the early prediction of outcome in patients with metastatic castration resistant prostate cancer on therapy with abirateroneacetate.. Journal of Clinical Oncology, 2016, 34, 241-241.	1.6	0
43	Early prediction of therapy response to abiraterone acetate using PSA subforms in patients with castration resistant prostate cancer.. Journal of Clinical Oncology, 2016, 34, e16586-e16586.	1.6	0
44	Influence of statins on survival outcomes in men with metastatic castration resistant prostate cancer treated with abiraterone.. Journal of Clinical Oncology, 2016, 34, e16573-e16573.	1.6	0
45	Benefit from next-generation ADT in AR-V7 positive patients.. Journal of Clinical Oncology, 2016, 34, e16532-e16532.	1.6	0
46	New radioligand therapy with <sup>177</sup> Lu-PSMA-617 in men with metastatic prostate cancer: Initial clinical experience after 50 therapy cycles.. Journal of Clinical Oncology, 2016, 34, e16575-e16575.	1.6	0
47	The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide. BMC Cancer, 2022, 22, 375.	2.6	0